All In Biotech

NDA 017378 · Baxter Hlthcare

Plasma-Lyte A In Plastic Container

Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, Sodium Gluconate · Injection

Last checked: Nov 19, 2026Latest source record: Aug 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Feb 2, 1979

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

59

55 serious, 11 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 5, 2019.

INDICATIONS AND USAGE PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is indicated as a source of water and electrolytes or as an alkalinizing agent.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 2, 1979 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • PLASMA-LYTE A IN PLASTIC CONTAINER · MAGNESIUM CHLORIDE 30MG/100ML; POTASSIUM CHLORIDE 37MG/100ML; SODIUM ACETATE 368MG/100ML; SODIUM CHLORIDE 526MG/100ML; SODIUM GLUCONATE 502MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER · MAGNESIUM CHLORIDE 30MG/100ML; POTASSIUM CHLORIDE 37MG/100ML; SODIUM ACETATE 368MG/100ML; SODIUM CHLORIDE 526MG/100ML; SODIUM GLUCONATE 502MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • acute kidney injury6
  • emotional distress6
  • pain6
  • renal failure6
  • respiratory failure6
  • anxiety5
  • injury5
  • pyrexia5
  • constipation4
  • death4
  • pneumonia4
  • pruritus4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20114
20121
20131
20144
20166
20173
20182
20194
20209
20211
20227
202312
20243
20251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Baxter Hlthcare · Also marketed as Plasma-Lyte 148 In Water In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.